Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC July Update

The Scottish Medicines Consortium has issued its monthly advice on new medicines.

Vildagliptin in combination with metformin (Eucreas®) has been accepted for restricted use (PDF). The combination should be used in patients for whom monotherapy with metformin provides insufficient glycaemic control and where the addition of a sulphonylurea is not appropriate. In this instance the addition of vildagliptin is an alternative to using glitazones.

Fesoterodine fumarate (Toviaz®) has also been accepted for restricted use (PDF). The advice notes that this drug is equivalent to existing therapies in terms of efficacy and also has a typical adverse event profile. The higher acquisition cost restricts this new drug to second-line use.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC July Update' on Email Share 'SMC July Update' on Delicious Share 'SMC July Update' on Digg Share 'SMC July Update' on Facebook Share 'SMC July Update' on Google+ Share 'SMC July Update' on reddit Share 'SMC July Update' on StumbleUpon Share 'SMC July Update' on Twitter

atomic-wealth

No Comments to “SMC July Update”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,518 spam comments.

atomic-wealth
fond-illness
summer